Texas attorney general sues insulin makers and pharmacy middlemen over high costs
Oct 3 (Reuters) -The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of collaborating to inflate the cost of insulin.
Texas Attorney General Ken Paxton's office said on Thursday it had sued insulin makers Eli Lilly LLY.N, Novo Nordisk NOVOb.CO and Sanofi SASY.PA.
The office had also sued PBMs, including CVS' CVS.N Caremark, Cigna's CI.N Express Scripts, and UnitedHealth's UNH.N OptumRx, who act as intermediaries in negotiating drug prices and coverage.
WHY IT'S IMPORTANT
The lawsuit targets both insulin manufacturers and PBMs. The previous action by U.S. antitrust regulators only targeted PBMs.
The U.S. Federal Trade Commission, in September, sued the same PBMs, accusing them of steering diabetes patients towards higher-priced insulin in order to secure millions of dollars in rebates from pharmaceutical companies.
At that time, the FTC had not sued the insulin manufacturers, but had criticized their role in what it called a broken system.
CONTEXT
In the Texas lawsuit, Paxton accused that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return.
The PBMs subsequently awarded preferred status to the manufacturer with the highest list prices, while excluding lower-priced drugs, the press release from the attorney general's office said.
KEY QUOTE
"Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could," said Paxton.
"Allegations that we play any role in determining the prices charged by manufacturers for their products are false, and we intend to vigorously defend against this baseless suit," said CVS in an emailed statement.
"Novo Nordisk believes that the allegations in the lawsuit are meritless, and we intend to vigorously defend against these claims," a company spokesperson told Reuters.
The other companies did not immediately respond to a request for comment.
Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
